Hikma Pharmaceuticals (LON:HIK) Price Target Lowered to GBX 2,400 at Deutsche Bank Aktiengesellschaft

Hikma Pharmaceuticals (LON:HIK) had its target price lowered by Deutsche Bank Aktiengesellschaft from GBX 2,500 to GBX 2,400 in a report published on Friday morning, Marketbeat.com reports. Deutsche Bank Aktiengesellschaft currently has a buy rating on the stock.

Other equities analysts have also issued reports about the company. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,360 price target on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. JPMorgan Chase & Co. cut their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating on the stock in a research note on Friday, November 7th. Berenberg Bank decreased their price target on shares of Hikma Pharmaceuticals from GBX 2,510 to GBX 2,300 and set a “buy” rating for the company in a research note on Thursday, November 6th. Finally, Peel Hunt reiterated a “buy” rating and set a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a report on Friday, November 7th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of GBX 2,326.

Hikma Pharmaceuticals Stock Up 1.3%

Shares of LON:HIK opened at GBX 1,569.54 on Friday. Hikma Pharmaceuticals has a 1 year low of GBX 1,482 and a 1 year high of GBX 2,360. The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The business’s 50-day moving average is GBX 1,568.67 and its 200-day moving average is GBX 1,740.27. The company has a market capitalization of £3.48 billion, a price-to-earnings ratio of 9.40, a P/E/G ratio of 2.38 and a beta of 0.41.

Insider Buying and Selling at Hikma Pharmaceuticals

In other news, insider Said Darwazah acquired 70,000 shares of the business’s stock in a transaction on Friday, November 7th. The shares were purchased at an average cost of GBX 1,541 per share, with a total value of £1,078,700. Also, insider Victoria Hull bought 3,214 shares of Hikma Pharmaceuticals stock in a transaction dated Friday, November 7th. The stock was purchased at an average price of GBX 1,547 per share, with a total value of £49,720.58. In the last three months, insiders have purchased 448,214 shares of company stock worth $712,497,058. Corporate insiders own 18.15% of the company’s stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.